Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies Corp (ADPT)
NASDAQ:ADPT
RESEARCH TOOLSreports
Adaptive Biotechnologies (ADPT) Stock Price & Analysis
787 Followers
ADPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.28 - $9.08
Previous Close$3.8
Volume2.06M
Average Volume (3M)1.76M
Market Cap
$560.00M
Enterprise Value$479.02M
Total Cash (Recent Filing)$308.87M
Total Debt (Recent Filing)$228.04M
Price to Earnings (P/E)-2.6
Beta2.04
Next Earnings
Jul 31, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding147,368,324
10 Day Avg. Volume1,445,877
30 Day Avg. Volume1,760,713
Standard Deviation0.17
R-Squared0.16
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)3.41
Price to Sales (P/S)13.37
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.75
Enterprise Value/Gross Profit5.06
Enterprise Value/Ebitda-3.44
Forecast
1Y Price Target
$6.33Price Target Upside66.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Adaptive Biotechnologies News
PremiumCompany Announcements
Adaptive Biotechnologies Names Kyle Piskel New CFO
Bulls Say, Bears Say
Bulls Say
Financial PerformanceADPT pre-announced 1Q revenues above the Street, indicating stronger than expected financial performance.
Market LeadershipADPT owns the blood-based MRD testing space in the clinic and with pharma, and is a valuable strategic asset in the market.
Regulatory DevelopmentThe FDA's ODAC voted in favor of utilizing MRD as a primary endpoint for accelerated approval of therapies, which is a positive regulatory development for the company.
Bears Say
Earnings ReportADPT reported a Q4 top-line miss with revenue of $45.8M, a decline of 17% year-over-year.
Executive MovementCFO Tycho Peterson to depart for another opportunity, to be succeeded by ADPT's current Principal Accounting Officer, Kyle Piskel.
Financial PerformanceIM revenues declined by -43% year-over-year, reflecting decreased amortization and a strategic shift towards target and drug discovery.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ADPT FAQ
What was Adaptive Biotechnologies Corp’s price range in the past 12 months?
Adaptive Biotechnologies Corp lowest stock price was $2.28 and its highest was $9.08 in the past 12 months.
What is Adaptive Biotechnologies Corp’s market cap?
Currently, no data Available
When is Adaptive Biotechnologies Corp’s upcoming earnings report date?
Adaptive Biotechnologies Corp’s upcoming earnings report date is Jul 31, 2024 which is in 78 days.
How were Adaptive Biotechnologies Corp’s earnings last quarter?
Adaptive Biotechnologies Corp released its earnings results on May 07, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.346 by $0.016.
Is Adaptive Biotechnologies Corp overvalued?
According to Wall Street analysts Adaptive Biotechnologies Corp’s price is currently Undervalued.
Does Adaptive Biotechnologies Corp pay dividends?
Adaptive Biotechnologies Corp does not currently pay dividends.
What is Adaptive Biotechnologies Corp’s EPS estimate?
Adaptive Biotechnologies Corp’s EPS estimate is -$0.33.
How many shares outstanding does Adaptive Biotechnologies Corp have?
Adaptive Biotechnologies Corp has 147,368,320 shares outstanding.
What happened to Adaptive Biotechnologies Corp’s price movement after its last earnings report?
Adaptive Biotechnologies Corp reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.346. Following the earnings report the stock price went up 2.251%.
Which hedge fund is a major shareholder of Adaptive Biotechnologies Corp?
Among the largest hedge funds holding Adaptive Biotechnologies Corp’s share is Viking Global Investors LP. It holds Adaptive Biotechnologies Corp’s shares valued at 147M.
---
Adaptive Biotechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.33 (66.58% Upside)
$6.33 (66.58% Upside)
Blogger Sentiment
Neutral
ADPT Sentiment 67%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.17%
12-Months-Change
Fundamentals
Return on Equity
-61.54%
Trailing 12-Months
Asset Growth
-21.62%
Trailing 12-Months
Company Description
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
---
ADPT Company Deck
---
ADPT Earnings Call
Q1 2024
0:00 / 0:00
---
ADPT Stock 12 Month Forecast
Average Price Target
$6.33
▲(66.58% Upside)
Technical Analysis
Best Analysts Covering ADPT
1 Year
1 Year Success Rate
3/24 ratings generated profit
1 Year Average Return
-43.04%
reiterated a buy rating 5 days ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -43.04% per trade.
---